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Dysregulation of the complement alternative pathway is involved in the pathogenesis 
of several diseases, including the kidney diseases atypical hemolytic uremic syndrome 
(aHUS) and C3 glomerulopathy (C3G). In a patient, initially diagnosed with chronic 
glomerulonephritis, possibly C3G, and who 6 years later had an episode of aHUS, a 
heterozygous missense mutation leading to a tryptophan to arginine exchange (W198R) 
in the factor H (FH) complement control protein (CCP) 3 domain has previously been 
identified. The aim of this study was to clarify the functional relevance of this mutation. To 
this end, wild-type (FH1–4WT) and mutant (FH1–4W198R) CCPs 1–4 of FH were expressed 
as recombinant proteins. The FH1–4W198R mutant showed decreased C3b binding com-
pared with FH1–4WT. FH1–4W198R had reduced cofactor and decay accelerating activity 
compared with the wild-type protein. Hemolysis assays demonstrated impaired capacity 
of FH1–4W198R to protect rabbit erythrocytes from human complement-mediated lysis, 
and also to prevent lysis of sheep erythrocytes in human serum induced by a monoclonal 
antibody binding in FH CCP5 domain, compared with that of FH1–4WT. Thus, the FH 
W198R exchange results in impaired complement alternative pathway regulation. The 
heterozygous nature of this mutation in the index patient may explain the manifestation 
of two diseases, likely due to different triggers leading to complement dysregulation in 
plasma or on cell surfaces.
Keywords: complement dysregulation, factor h, c3 glomerulopathy, atypical hemolytic uremic syndrome, 
mutation, kidney disease
inTrODUcTiOn
Complement alternative pathway dysregulation is implicated in the pathogenesis of several diseases, 
including the renal diseases C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome 
(aHUS) (1, 2). C3G is an umbrella term that covers a spectrum of clinically heterogeneous rare kidney 
diseases characterized by common underlying pathogenic mechanisms; its two main subclasses are 
Abbreviations: aHUS, atypical hemolytic uremic syndrome; C3G, C3 glomerulopathy; CCP, complement control protein 
domain; FH, factor H; FI, factor I; TMA, thrombotic microangiopathy.
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dense deposit disease and C3 glomerulonephritis, characterized 
by deposition of C3 fragments in the glomeruli but differentiated 
based on the presence of electron dense deposits in the case of 
dense deposit disease upon electron microscopical analysis (3). 
aHUS is a thrombotic microangiopathy (TMA) characterized by 
erythrocyte fragmentation, low platelet count, and acute kidney 
failure (4–6).
These distinct disease entities have partly common underly-
ing genetic and acquired susceptibility factors, and thus, shared 
pathological mechanism related to complement dysfunction 
(2, 7, 8). C3G is most commonly associated with C3 nephritic 
factor, an autoantibody that stabilizes the C3 convertase (C3bBb) 
and thus leads to enhanced complement activation (9, 10). In 
addition, anti-factor H (FH) autoantibodies that bind the N ter-
minus of FH and prevent the FH-mediated fluid-phase regulation 
of C3bBb (11–13), and anti-factor B and anti-C3b autoantibodies 
that stabilize the C3bBb convertase, are described in C3G (10, 
14–16). Similarly, C5 nephritic factors stabilize the C5 con-
vertase and are associated with C3G (17). More rarely, genetic 
disease predisposing factors are identified in C3G patients. These 
include complement factor H (CFH) risk variants and mutations 
(18–22), CFHR1 mutation (23), CFHR5 mutation (24), and 
hybrid CFHR3::CFHR1, CFHR2::CFHR5, CFHR5::CFHR2, and 
CFHR1::CFHR5 genes (25–28). In aHUS, variations of several 
complement genes have been described as susceptibility factors, 
among which FH variations being the most common (in ~30% of 
the patients) (5). In addition, FH autoantibodies may be present 
in aHUS and are strongly associated with the deletion of the 
CFHR1 gene (29–31).
Factor H is the main soluble regulatory protein of the alterna-
tive pathway (32–34). FH inhibits the activation of the alternative 
pathway by three mechanisms: by acting as a cofactor for the 
serine protease factor I (FI) in the enzymatic cleavage and thus 
inactivation of C3b (“cofactor activity”), by preventing the assem-
bly of the C3bBb C3 convertase enzyme, and by accelerating the 
decay of this convertase if already formed (“decay accelerating 
activity”) (35–37). FH does not only act in the fluid phase, i.e., 
in body fluids, but it can also bind to and protect host cells and 
surfaces from complement attack [reviewed in Ref. (32)]. FH is 
composed of 20 complement control protein (CCP) domains. The 
C-terminal CCP19–20 domains allow FH to recognize host sur-
faces under complement attack, i.e., deposited C3b in the context 
of host polyanionic molecules, such as sialic acid (38). The FH 
N-terminal CCP1–4 domains mediate binding to C3b, cofactor 
activity for FI, and acceleration of the decay of the alternative 
pathway C3bBb convertase (39).
Mutations in FH may lead to quantitative or qualitative FH 
deficiency and are associated with diseases (40). Some of the 
mutations cause secretion defect or early stop codons and thus 
result in truncated or undetectable FH protein in plasma (41, 
42). Other mutations cause functional impairment in otherwise 
normally secreted FH (20, 40). Similarly, autoantibodies binding 
primarily in the main functional domains inhibit either the regu-
latory or the host cell/surface binding functions of FH [reviewed 
in Ref. (10)]. In general, mutations and autoantibodies affecting 
the N-terminal regulatory domains of FH cause alternative path-
way dysregulation in plasma, leading to plasma C3 consumption 
and deposition of C3 fragments in the glomeruli, and are associ-
ated with C3G. On the other hand, mutations and autoantibodies 
interfering with the C-terminal host recognition domains of FH 
usually cause complement dysregulation on surfaces, such as 
the glomerular endothelium and basement membrane, and are 
associated with aHUS (2, 5, 9, 32).
Most functionally characterized FH mutations to date were 
those affecting the C terminus and are associated with aHUS. 
Relatively few missense mutations were reported in the CCP1–4 
region (43). Recently, a FH mutation in CCP1 associated with 
familial membranoproliferative glomerulonephritis (MPGN) 
(22) and one in CCP3 related with aHUS (44) were described. 
Thus, while mutations and autoantibodies affecting the FH C 
terminus are in general associated with aHUS, and mutations 
and autoantibodies affecting CCP1–4 are usually associated with 
C3G, the picture is not that simple (8, 10, 45, 46). N-terminal 
FH mutations causing alternative pathway dysregulation may 
be associated with different diseases. In addition, some identi-
fied gene variants may have no functional significance (47), or 
result in increased complement regulatory activity of FH (48). 
Therefore, it is important to characterize the mutant proteins in 
functional assays to identify those variants that have pathological 
relevance.
Previously, we reported novel aHUS-associated FH muta-
tions, including a patient heterozygous for the N-terminal FH 
mutation c.592T >  C leading to the W198R exchange (44). 
In the current study, we describe the functional characteriza-
tion of this mutation that manifested in two different kidney 
diseases in the patient. The mutation is localized in the CCP3 
domain and leads to functional FH deficiency, as we show that 
this mutation disrupts the main functions of the N-terminal 
portion of FH.
MaTerials anD MeThODs
The patient gave written informed consent in accordance with the 
Declaration of Helsinki. Written approval for the diagnostic tests 
and genetic analysis was given by the patient. Relevant clinical 
and laboratory data were collected from hospital records, accord-
ing to the protocol approved by the institutional review board of 
Semmelweis University and the National Ethical Committee of 
Hungary.
generation of Fh 1–4 Mutant
Codon-optimized FH CCPs 1–4 fragment (FH1–4) (49) was 
generated by commercial gene synthesis (GenScript, Piscataway, 
NJ, USA) and cloned into the pBSV-8His Baculovirus expression 
vector using PstI and SmaI enzymes, as previously described 
(50). Codon-optimized FH1–4 containing the W198R exchange 
was synthetized (IDT, Coralville, IA, USA) and cloned into the 
pBSV-8His vector using PstI and SmaI enzymes (50). The cloned 
constructs were verified by sequencing to ensure that the recom-
binant protein carried exclusively the W198R mutation. Both 
proteins were expressed in Spodoptera frugiperda (Sf9) insect 
cells using Insect-XPRESS™ Protein-free Insect Cell Medium 
(Lonza) and purified from the cell culture supernatants by affinity 
chromatography using an anti-FH column.
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Proteins, abs, and sera
Purified human FH, factor B (FB), factor D (FD), properdin (fac-
tor P), C3b, FI, goat anti-human FH Ab, and goat anti-human FB 
Ab were obtained from Merck (Budapest, Hungary). The anti-FH 
mAb A254 was purchased from Quidel (Biomedica; Budapest, 
Hungary), and mAb OX24 was from Santa Cruz Biotechnology. 
HRP-conjugated goat anti-human C3 was purchased from MP 
Biomedicals (Solon, OH, USA). HRP-conjugated rabbit anti-
goat Ig and HRP-conjugated goat anti-mouse Ig were from Dako 
(Hamburg, Germany). Bovine serum albumin (BSA) was from 
Applichem (Darmstadt, Germany). Normal human plasma was 
collected from healthy individuals after informed consent and 
pooled.
sequence analysis
Nucleotide and protein sequences were analyzed using the 
Bioinformatics Research Portal (ExPasy) of the Swiss Institute of 
Bioinformatics (http://www.expasy.org), to analyze the transla-
tion, molecular weight, and other parameters by the ProtParam 
tool. The position of the mutation was visualized using PyMol 
on the structure of the C3b in complex with FH1–4 (PDB ID 
2WII) (51).
c3b Binding assays
To compare the binding of C3b to FH1–4WT and FH1–4W198R 
by ELISA, microtiter plate wells were coated with 100  nM of 
FH1–4WT and FH1–4W198R in Dulbecco’s PBS (DPBS; Lonza) at 
20°C for 1 h. The wells were washed after each step with DPBS 
containing 0.05% Tween-20. After blocking with 5% BSA in 
DPBS-Tween for 1 h, serial dilution of C3b was added in DPBS 
at 20°C for 1 h. Bound C3b was detected with HRP-conjugated 
anti-C3 antibody, using 3,3′,5,5′-tetramethylbenzidine (TMB) 
(BioLegend; Biomedica, Budapest, Hungary) as chromogen and 
reading the absorbance at 450 nm.
The interaction of FH1–4WT and FH1–4W198R with C3b was also 
analyzed by surface plasmon resonance, using ProteOn XPR36 
equipment (BioRad). Recombinant FH1–4WT and FH1–4W198R 
were diluted in acetate buffer (pH 4.0) and immobilized on 
two parallel flowcells on a GLC biosensor chip using a standard 
amine coupling protocol, as recommended by the manufacturer, 
to achieve a coupling density of ~3,500 RU for the two proteins. 
Serial dilutions of C3b were used as analytes, diluted in PBS con-
taining 0.005% Tween-20 and 145 mM NaCl as running buffer 
at a flow rate of 30 µl/min. Association was followed for 300  s 
and the dissociation for 600 s. Data were analyzed with ProteOn 
manager software.
c3bBb-Decay assay
The C3bBb convertase was generated on C3b immobilized at 
5 µg/ml in microtiter plate wells in DPBS, as described previously 
(52). Briefly, the wells were washed with DPBS containing 0.05% 
Tween-20 and blocked for 1  h at 20°C with DPBS containing 
5% BSA. FB (2 µg/ml), FD (0.1 µg/ml), and properdin (4 µg/ml) 
were added in convertase buffer (4% BSA, 2  mM Ni2+, 0.1% 
Tween-20 in DPBS containing Ca2+ and Mg2+) in 50 µl for 30 min 
at 37°C. Decay acceleration was analyzed by adding increasing 
concentrations of FH1–4WT and FH1–4W198R, 50  nM FH and 
50 nM HSA for 60 min at 37°C. Remaining intact convertases 
were detected using polyclonal anti-FB antibody and the cor-
responding secondary antibody. Color reaction was developed 
with TMB and the absorbance was read at 450 nm.
cofactor assay
Cofactor activity of FH1–4WT and FH1–4W198R was measured 
in fluid-phase by incubating 220  nM C3b and 440  nM FI 
with 10 and 50  nM FH, FH1–4WT and FH1–4W198R for 1  h at 
37°C in a final volume of 28 µl. The reactions were stopped by 
adding reducing SDS-sample buffer. Samples were separated 
on 10% SDS-PAGE gel and subjected to Western blot. The 
membrane was blocked with DPBS containing 4% BSA and 
1% skimmed milk powder. C3 fragments were detected using 
HRP-conjugated goat anti-human C3 antibody and an ECL 
detection kit (Merck).
hemolysis assays
Sheep red blood cells (SRBCs; Culex Bt., Budapest, Hungary) 
were washed three times in veronal buffer containing 10  mM 
Mg2+-EGTA (Lonza; Biocenter, Szeged, Hungary). FH1–4WT 
and FH1–4W198R were added in 125–1,000 nM concentration to 
2% SRBCs and 15% human serum with 1.5 µg mAb OX24 in a 
final volume of 60  µl in veronal buffer, and incubated at 37°C 
for 30 min. SRBCs were sedimented by centrifugation and the 
released hemoglobin was measured at 405 nm.
To determine the capacity of FH1–4WT and FH1–4W198R to 
reverse the alternative pathway-mediated lysis of rabbit red blood 
cells (RRBCs; kind gift of Á. Mikesy, Budapest), the recombinant 
proteins were added in 1 µM concentration to 2% RRBCs and 
5% human serum in a final volume of 60  µl in veronal buffer 
containing 10 mM Mg2+-EGTA. Samples were incubated at 37°C 
for 30 min, and hemolysis was measured as above.
resUlTs
Patient Description
In 2006, a 20-year-old man was admitted for evaluation of hema-
turia, proteinuria (protein/creatinine 0.83 g/g), and hyperten-
sion. He had a normal kidney function (creatinine 0.9 mg/dl), 
urine microscopy revealed dysmorphic hematuria. Laboratory 
analysis showed normal values for anti-nuclear antibodies, anti-
neutrophil cytoplasmic antibodies, IgA, and complement C4. The 
only notable abnormality was a slightly decreased serum-com-
plement C3c level (0.872 mg/ml; normal range: 0.9–1.8 mg/ml). 
The diagnosis of chronic glomerulonephritis was made. The 
patient was treated with an ACE-inhibitor and scheduled for 
short-term follow-up visits with the prospective of a renal 
biopsy in case of increasing proteinuria or worsening kidney 
function. Unfortunately, the patient did not reappear for the 
scheduled visits.
In 2012, the patient was admitted to our intensive care unit 
with end-stage renal disease, malignant hypertension, and 
pulmonary edema, and laboratory results consistent with TMA 
(platelet count 109  G/l, LDH 1,136 U/l, and haptoglobin not 
FigUre 1 | Family tree of the patient’s family. The family tree shows the 
occurrence of the complement factor H (CFH) W198R mutation in 
heterozygosis in the mother and the index patient. All investigated family 
members carry the membrane cofactor protein risk haplotype (MCPggaac) in 
heterozygosis. The patient is indicated with an asterisk, all other family 
members are healthy (44).
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detectable). C3c was markedly decreased (0.49  mg/ml). The 
patient was started on hemodialysis. A diagnosis of aHUS was 
considered, but with better blood pressure control the laboratory 
parameters of TMA quickly normalized. The patient remained 
on chronic dialysis treatment. Because of a possible diagnosis 
of aHUS, and the fear of a relapse after transplantation and the 
need for eculizumab, the patient received full antimeningococcal 
vaccination.
In October 2013, the patient’s samples were sent to the 3rd 
Department of Internal Medicine, Semmelweis University, 
for further complement measurements during the diagnostic 
work-up, and the following concentrations were observed (with 
the reference ranges shown): 0.8 mg/ml of C3 (0.9–1.8 mg/ml), 
400 mg/l of FH (250–880 mg/l), 114% of FI, and 63% of factor 
B (70–130% for the latter two, expressed in the percent of the 
normal human serum pool).
In March 2015, he received a full-house HLA-identical kidney 
graft from a deceased donor. Because of the assumption that the 
patient may have aHUS as underlying disease, calcineurin inhibi-
tors were avoided and the initial immunosuppression consisted 
of belatacept, mycophenolic acid, and steroids. Despite optimal 
HLA-matching the patient suffered from delayed graft function 
for 3  weeks. A transplant biopsy showed severe acute cellular 
vascular rejection (BANFF 2b). The patient was treated with 
high-dose steroids and antithymocyte globulin and transplant 
function improved. 2  weeks later, a sudden elevation of LDH 
and decrease of serum haptoglobin were noted. Thrombocytes 
fell from 300G/l to 175G/l, and fragmentocytes were detected, 
suggestive of a diagnosis of TMA. The patient had severe hyper-
tension. Assuming recurrence of aHUS, the patient was given 
a single dose of eculizumab (900  mg). However, an urgently 
performed second transplant biopsy showed marked narrowing 
of arterioles due to hyalinosis without any signs of TMA, there-
fore, eculizumab was not administered more than once. After 
consequent antihypertensive treatment all parameters of intra-
vascular hemolysis resolved. The further posttransplant course 
was unremarkable and the patient’s current serum creatinine is 
1.7  mg/dl corresponding to an estimated glomerular filtration 
rate of 51 ml/min/1.73 m2.
The patient’s current immunosuppression consists of belata-
cept 250 mg every 4 weeks, mycophenolate sodium 720 mg and 
prednisolone 5 mg. Antihypertensive medication includes valsar-
tan, amlodipin, doxazosin, metoprolol, and hydrochlorothiazide.
While screening for mutations, the whole coding regions of 
the genes encoding complement factor H (CFH), factor I (CFI), 
membrane cofactor protein (CD46), thrombomodulin, factor B 
(CFB), and C3 (C3) were analyzed by direct DNA sequencing fol-
lowing PCR amplification. Upon genetic analysis, the membrane 
cofactor protein risk haplotype (MCPggaac) (53) was identified 
in the patient, his mother, and two brothers in heterozygosis. 
The patient and his mother are heterozygous for the FH muta-
tion W198R, as we reported previously (44). Her serum C3 level 
was slightly reduced (0.82 mg/ml). However, she had no sign of 
kidney disease. The two brothers of the patient do not carry the 
FH W198R mutation (we did not receive samples to measure the 
serum C3 levels in the two brothers) (Figure 1) (44).
generation of Fh1–4WT and Fh1–4W198r
In order to assess the functional impact of the W198R muta-
tion, we generated a wild-type (FH1–4WT) and a mutant form 
(FH1–4W198R) of the complement regulatory domains of FH 
that were expressed as recombinant proteins in insect cells. The 
W198R mutation is located in one of the regulatory domains 
(CCP3) and affects the conserved Trp residue of the CCP 
domain (Figure 2A). The substitution is expected to perturb the 
local fold, since the Trp side chain is oriented to the interior of 
the domain and maintains its structure (Figure 2B). However, 
we did not observe a secretion defect or instability of the recom-
binant protein (Figure  2C). In line with this, the patient had 
normal FH level (400 µg/ml), thus the mutation is unlikely to 
lead to partial FH deficiency due to unstable protein produced 
by the affected allele.
W198r impairs c3b Binding of Fh
As the 3D structure of the FH CCPs 1–4 with C3b shows 
(Figure  2B), the Trp residue is only partially exposed to the 
surface, opposite to the one in contact with C3b. The introduction 
of a positive charge at this place would result in the disruption of 
the local structure. Therefore, even if the residue is at the opposite 
surface and not a contact one with C3b, the structural change 
could be strong enough to cause a loss of C3b binding.
To test if the mutation affects binding of the main ligand C3b, 
we immobilized FH1–4WT and FH1–4W198R in equimolar amounts 
in microplate wells. Increasing concentrations of purified C3b 
were added, and bound C3b was detected with a polyclonal 
antibody in ELISA. Both the wild-type and the mutant FH1–4 
bound C3b in a dose-dependent manner; however, the capability 
of FH1–4W198R to bind C3b was significantly reduced compared 
with FH1–4WT (Figure 3A). The interaction with C3b was also 
analyzed by surface plasmon resonance. The FH1–4W198R and 
FH1–4WT were immobilized on the chip surface and C3b was 
flowed over the cells. In this set-up, the FH1–4W198R practically 
showed no C3b binding (Figure  3B). Altogether, these results 
FigUre 3 | Analysis of C3b-binding capacity of FH1–4W198R by ELISA and SPR. (a) Both the wild-type and the mutant proteins were immobilized in microtiter plate 
wells at 100 nM. Serial dilutions of C3b were added and its binding was detected with anti-C3 antibody. Data are mean ± SD from three experiments. The binding 
of C3b to FH1–4W198R was significantly weaker than to FH1–4WT (p = 0.0003 two-way ANOVA; **p < 0.01). (B) SPR analysis of the interaction of the immobilized 
FH1–4WT and FH1–4W198R with serial dilutions of C3b in the fluid phase. PBS-0.005% Tween 20 was used as a running buffer, with a flow rate of 30 µl/min.
FigUre 2 | Location of W198R in FH, and generation of mutant FH1-4 fragment. (a) FH has 20 complement control protein domains (CCPs). The N-terminal CCPs 
1–4 are responsible for complement regulation (light gray), and the CCPs 19–20 are host surface recognition domains (dark gray). The position of the mutation is 
showed with other previously characterized mutations. W198R is located in CCP3. References: 1 (54), 2 (55), 3 (22), 4 (42); 5 (56), 6 (57), 7 (44), 8 (20). (B) Left, 3D 
structure of the mutant FH CCPs 1–4 (light gray) with C3b (dark gray) based on the known co-crystal structure of FH CCPs 1–4 and C3b (PDB 2WII) (51) (visualized 
using PyMol). The surface representation of the residues is shown. Right, close-up view of the FH region containing the mutated residue shown as cartoon 
representation. The Trp residue, shown in black as a stick model, is only partially exposed to the surface, opposite to the one in contact with C3b. The substitution 
to Arg is expected to perturb the local fold, since the Trp side chain is oriented to the interior of the domain. (c) Recombinant mutant FH1–4 was expressed in 
insect cells. 1 and 2 µg of the purified wild-type and mutant FH CCPs 1–4 were run on 12% SDS-PAGE and stained with silver nitrate. The molecular mass marker 
is shown on the left side (kDa).
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indicated that the mutation results in a strongly reduced capacity 
of FH to bind C3b via its N terminus.
W198r impairs cofactor and Decay 
accelerating activity of Fh
Because of the reduced C3b binding, we examined whether 
this mutation influences the regulatory functions of FH. First, 
we tested the decay of the solid-phase alternative pathway C3 
convertase (C3bBb) assembled on an ELISA plate. Increasing 
concentrations of the mutant and wild-type FH1–4 fragments 
were added, and the remaining convertase was monitored 
using a factor B-specific antibody. While both FH1–4W198R and 
FH1–4WT dissociated the convertase in a dose-dependent man-
ner, the mutant form had significantly less capacity to accelerate 
convertase decay (Figure 4A).
FigUre 4 | Decay accelerating- and cofactor activity of FH1–4W198R.  
(a) Decay acceleration assay. The alternative pathway C3 convertase 
(C3bBb) was built up on microtiter plate. FH1–4WT and FH1–4W198R were 
added for 1 h, and the remaining intact convertase was detected using 
anti-factor B antibody. The capacity of FH1–4W198R to accelerate 
convertase decay was significantly impaired compared with FH1–4WT 
(p < 0.0005, two-way ANOVA; *p < 0.05). Data are mean ± SD from three 
experiments. (B) The cofactor activity of FH1–4WT and FH1–4W198R in the 
fluid phase was measured by incubating 220 nM C3b and 440 nM FI with 
the indicated concentrations of FH1–4WT and FH1–4W198R at 37°C for 1 h. 
To stop the reaction, reducing sample buffer was added, and the samples 
were subjected to 10% SDS-PAGE and Western blotting. To visualize the 
C3b proteolysis, HRP-conjugated polyclonal anti-human C3 antibody was 
used. The blot is representative of two experiments.
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W198r causes reduced Protection of 
host-like cells from complement-
Mediated lysis
To analyze the effect of the mutation on cellular protection 
against complement activation, various hemolysis assays were 
used. Hemolysis assays using sheep red blood cells (SRBCs) are 
commonly used to evaluate the capacity of FH to protect host-
like cells from complement-mediated lysis, because—similar 
to human cells—FH can bind to surface exposed polyanionic 
molecules, likely sialic acid, on the surface of SRBCs (58). First, 
we induced lysis of SRBCs with the OX24 mAb, which binds to 
CCP5 of FH and inhibits the complement regulatory activity of 
FH in serum but also when FH is bound to the cells. We con-
firmed in ELISA that this mAb does not bind to the generated 
wild-type and mutant FH1–4 (Figure 5A). To inhibit the com-
plement activation in the fluid-phase and thus prevent bystander 
lysis of SRBCs, increasing concentrations of FH1–4W198R and 
FH1–4WT were added. Both FH1–4 constructs reduced SRBC 
lysis in a dose-dependent manner; however, in this functional 
assay, the FH1–4W198R was less effective to prevent hemolysis than 
the wild-type protein (Figure  5B). Even when added in 1  µM 
concentration, FH1–4W198R could only slightly reduce hemolysis, 
which activity was significantly weaker than that of FH1–4WT 
(Figure 5C).
We also examined the alternative pathway mediated lysis of 
rabbit erythrocytes (RRBCs). Because FH cannot bind to rab-
bit erythrocytes due to the lack of sialic acids on their surface, 
normal human serum causes dose-dependent lysis of RRBCs. In 
this assay, FH1–4W198R when added at 1 µM concentration did not 
protect the RRBCs from complement-mediated lysis, whereas 
FH1–4WT strongly inhibited RRBC lysis (Figure 6).
DiscUssiOn
The kidney diseases associated with complement alternative 
path way dysregulation may represent a spectrum of related dis-
orders, with overlapping underlying genetic or acquired factors 
identified in distinct disease entities (7, 8). It is important to func-
tionally characterize the identified genetic changes, because they 
may represent polymorphisms with no functional significance 
(47). In this study, we describe the functional consequences of 
the FH W198R mutation by comparing the recombinant wild-
type and mutant complement regulatory domains (i.e., FH1–4). 
This missense mutation results in a strong reduction of the 
complement regulatory activity.
The soluble complement inhibitor FH plays an important 
role in both plasma and at cellular and non-cellular surfaces, 
such as the glomerular basement membrane in the kidney. FH 
deficiency and thus uncontrolled alternative pathway activation 
lead to various diseases from aHUS to C3G. Very low level, com-
plete absence in plasma or functional inactivation of FH result 
in continuous C3-fragment deposition in the glomeruli and 
usually manifest as C3G. The W198R mutation does not lead to 
quantitative FH deficiency, because the serum FH level was nor-
mal in the patient. However, a partial functional FH deficiency is 
evident from the in vitro characterization of the mutant protein 
Next, we tested the effect of the mutation on the FH cofactor 
activity in fluid phase. C3b cleavage by the serine protease FI in 
the presence of equimolar amounts of FH1–4W198R, FH1–4WT, 
and FH as control, was measured by detecting the generated C3b 
fragments by Western blot. At 10 nM concentration, both FH and 
FH1–4WT acted efficiently as cofactors for FI, demonstrated by 
the cleavage of the C3b α′ chain into 68- and 43-kDa fragments. 
Under these conditions, when FH1–4W198R was added as cofactor, 
no C3b cleavage was apparent (Figure 4B). At increased, 50 nM 
concentration FH1–4W198R displayed weak cofactor activity that 
was still strongly reduced compared with the activity of 10 nM 
FH1–4WT.
Altogether, these data demonstrate that the W198R 
exchange results in reduced binding of fluid-phase C3b and, 
as a consequence, reduced fluid-phase cofactor activity and 
surface-bound convertase decay accelerating activity of FH.
FigUre 6 | Impaired capacity of FH1–4W198R to protect rabbit red blood cells 
(RRBCs) from human complement-mediated lysis. RRBCs were incubated 
with 5% normal human serum. RRBCs cannot bind FH because of the lack 
of sialic acids on their surface; therefore, they are lysed by serum 
complement. FH added to the serum in excess can inhibit complement 
activation and reduce complement-mediated lysis of RRBCs. To quantify and 
compare the capacity of FH1–4WT and FH1–4W198R to inhibit complement 
activation in serum, FH1–4WT/FH1–4W198R were added in 1 µM concentration, 
the samples were incubated at 37°C for 30 min, then the released 
hemoglobin in the supernatants was measured at 405 nm. RRBC lysis in 
serum without the addition of FH1–4 was set to 100%. Data are mean + SD 
of three independent experiments (*p < 0.05, **p < 0.01, one-way ANOVA).
FigUre 5 | Impaired capacity of FH1–4W198R to protect sheep red blood cells 
(SRBCs) from complement-mediated lysis. (a) The binding of mAb OX24, 
which was used to induce SRBC lysis, to immobilized FH1–4WT and 
FH1–4W198R, as well as to factor H (FH) and bovine serum albumin (BSA), 
used as positive and negative controls, respectively, was measured in ELISA. 
Reactivity of the mAb A254 that binds in CCP1 of FH is also shown as a 
control. A representative ELISA result is shown. (B) 15% normal human 
serum was mixed with 1.5 µg OX24 antibody, which binds in FH CCP5, to 
induce lysis of SRBCs. Samples included increasing concentrations of 
FH1–4WT/FH1–4W198R. After incubating at 37°C for 30 min, the released 
hemoglobin in the supernatants was measured at 405 nm. A representative 
experiment is shown. (c) To quantify and compare the capacity of wild-type 
and mutant FH1–4 at high concentration to inhibit complement activation in 
serum, OX24-induced SRBC lysis was measured in the presence of 1 µM 
FH1–4WT and FH1–4W198R. SRBC lysis in the sample without the addition of 
FH1–4 was set to 100%. Data are mean + SD of four independent 
experiments (*p < 0.05, ***p < 0.001, one-way ANOVA).
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(Figures 3–6). Previous in silico analysis predicted a deleterious 
effect of the mutation, and a hemolytic test indicated abnormally, 
but not dramatically, elevated hemolysis of SRBCs in the pres-
ence of the patient’s serum (44). In the current study, we found 
strongly reduced C3b binding in the case of the mutant protein 
(Figure 3). Compared to the ELISA, the SPR approach showed 
complete lack of C3b binding for FH1–4W198R. This difference 
may be due to the different surface protein densities in the two 
assays, the different buffers (while the ionic strength was similar, 
in the SPR experiments the buffer contained 0.005% Tween-20), 
and the short (300 s) contact time in the SPR versus long incuba-
tion time (1 h) in the ELISA. The longer incubation and steady 
state condition in the ELISA allow the formation of detectable 
amount of the low affinity FH1–4W198R—C3b complexes, which 
is not supported by the stringent conditions in the SPR measure-
ment. In addition, in the ELISA, the detection of the formed 
complexes is enhanced by an additional step using the anti-C3 
antibody and by the enzyme conjugated to the antibody. In any 
case, a significant reduction of C3b binding by FH1–4W198R in 
comparison with FH1–4WT was evident, which translated into a 
dramatic impairment of complement regulation by FH in both 
fluid-phase and solid-phase assays, as well as in cell surface 
protection assays.
The mutation is located at the surface of CCP3, opposite to 
the contact interface with C3b (Figure 2B). The decreased C3b 
binding could be explained by a major conformational change, 
affecting the entire domain, caused by the replacement of a large 
aromatic aminoacid with a charged one. The profound pertur-
bation of the FI cofactor activity could be a synergistic effect 
between decreased C3b binding and decreased binding of FI to 
the C3b-mutant FH complex, since the mutation is located very 
close to the FI binding site in CCP3 of FH (59).
This N-terminal FH mutation manifested sequentially as 
glomerulonephritis (possibly C3G) and then aHUS in the 
same patient. The patient is heterozygous for the W198R 
mutation; he had normal FH serum levels and it was not 
possible to determine whether the wild-type and mutant FH 
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alleles were expressed differently. Our previous results of 
SRBC hemolysis in the serum of the patient (44) indicates that 
both FH variants are expressed, and the recombinant protein 
was also expressed and stable (Figure 2C). It is likely that the 
reduced amount of functionally active FH would not be able 
to cope with too strong complement activation in plasma, and 
the balance would be tipped in favor of activation instead of 
inhibition. This mutation is in the FH N terminus and not in 
the C-terminal domains CCPs 18–20 that are mainly responsi-
ble for host surface recognition and implicated in aHUS, thus 
both the mutant and the wild-type FH in the patient could 
bind to surfaces such as glomerular endothelial cells and the 
basement membrane. However, due to the affected regulatory 
domains in the mutant protein, this would result in subopti-
mal surface protection against complement attack that could 
be overwhelmed under conditions of too strong complement 
activation.
It is notable that our patient presented in 2012 with malig-
nant hypertension and moderate hematologic activity of TMA. 
A subset of patients with hypertension-associated TMA falls 
within the spectrum of complement-mediated TMA (60), and 
our patient is an example of this. Phenotype transitions in 
patients have been described earlier, such as mesangio-capillary 
glomerulonephritis with initial presentation of aHUS (61), and 
MPGN with transition to aHUS associated with FH mutations 
R53C (CCP1) and I216T (CCP4) (62, 63).
To date, only a few N-terminal FH mutations were character-
ized in detail. A homozygous deletion of K224 in CCP4 resulted 
in a functionally inactive FH and caused dense deposit disease 
(20). The heterozygous R83S mutation in CCP1 was shown 
to lead to impaired C3b binding, reduced cofactor, and decay 
accelerating activities and was associated with MPGN with 
acquired partial lipodystrophy (22). Two mutations affecting FH 
CCP1 R53H and R78G, both reported in aHUS patients and the 
latter in homozygosis, were characterized, and similarly defec-
tive complement regulating capacity of the mutants were found 
(54, 55). The homozygous R127L mutation in FH CCP2 was 
described in two brothers with undetectable serum FH levels 
who developed MPGN (42). Similarly, the homozygous R127H 
mutation caused complete lack of circulating FH in a boy with 
severe recurrent pneumonia but without renal manifestation; 
the mutant protein was later characterized and shown that albeit 
the mutant FH had normal cofactor activity, it was retained 
intracellularly (56, 57).
In summary, our results demonstrate that the FH W198R 
exchange results in impaired complement alternative pathway 
regulation. The heterozygous nature of this mutation in the 
index patient may explain the manifestation of two complement-
mediated kidney diseases several years apart, likely due to differ-
ent triggers leading to complement dysregulation in plasma or 
on cell surfaces.
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